Cohort event monitoring of patients treated for uncomplicated malaria with artemisinin-based combination therapies in selected hospitals and community pharmacies in Nigeria
| Autor: | Cassandra Elagbaje, PU Bassi, AA Amodu, Adeline Osakwe, Iliya Jalo, CG Ugochukwu, VO Adegoke, Eno Etim Nyong, M Kalat, K Dabit, II Bob-Okon, FN Ejiekpe, AO Adesina, Olayinka O Ogunleye, Comfort Kunak Suku, Ambrose O. Isah, S Ayinbuomwan, G Ntadom, S Nwaosu, Robinson D. Wammanda, J P Ambe, S T Balogun, R Tahir, AT Habib, Y Mava, F Onuoha |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pediatrics
medicine.medical_specialty Nigeria 030226 pharmacology & pharmacy Uncomplicated malaria 03 medical and health sciences Antimalarials 0302 clinical medicine medicine Humans Artemisinin Adverse effect Pharmacies Community pharmacies Fluorenes business.industry Incidence (epidemiology) General Medicine medicine.disease Artemisinins Malaria Drug Combinations Treatment Outcome Ethanolamines Cohort Vomiting medicine.symptom business medicine.drug |
| Zdroj: | The Nigerian postgraduate medical journal. 23(4) |
| ISSN: | 1117-1936 |
| Popis: | Aims and Objectives: The study was designed with the broad objective of determining the safety profile of artemisinin-based combination therapies amongst Nigerian population. Patients and Methods: This was a cohort event monitoring (CEM) programme involving monitoring adverse events (AEs) in malaria patients treated with either artemether-lumefantrine (AL) or artesunate-amodiaquine (AA) in healthcare facilities in Nigeria. The study involved continuous enrolment of patients with malaria and treated with either AL or AA at the various sites until a total cohort of 600 patients were enrolled at each site. Patients were monitored from the onset of therapy, and on days 3 and 7 from the first day of treatment to identify AEs that may occur. Results: A total of 6102 AEs were recorded in 10,259 patients monitored during the programme. Of 4896 patients who received AA, 4233 (86.5%) patients reported at least one AE while 1869 (34.8%) AEs out of 5363 patients who received AL were reported (P = 0.010). The predominant incidence of each specific AE reported in each group among the patients who received AA and AL includes body weakness 30.8%/7.5%, dizziness 10.3%/3.9%, restlessness 5.02/1.12%, vomiting 3.5/1.03% and drowsiness 3.1/1.5% for AA and AL, respectively. There were more AEs among patients with co-morbid conditions and patients in the younger age groups (9 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|